Evid Based Nurs 13:107-108 doi:10.1136/ebn1002
  • Prevalence
  • Cross-sectional

Severe adverse reactions are rare with infusions of infliximab in a community setting

  1. Yusuf Yazici
  1. New York University School of Medicine, NYU Hospital for Joint Diseases, New York, USA
  1. Correspondence to Yusuf Yazici
    246 East 20th Street, New York, NY 10003, USA; yusuf.yazici{at}

Commentary on:

In this study, Ducharme and colleagues report on the experience in community infusion centres with patients using infliximab for a variety of indications. As the authors state, randomised clinical trials are not the ideal environment to assess safety,1 2 and ‘real-world’ experience after the drugs are available to use give us a more complete picture for both the efficacy and the safety of any medication. This is a commendable effort that will provide important information for practitioners and patients alike.

In this retrospective chart review study, all infusions …

This article has not yet been cited by other articles.

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article